Evommune (EVMN) grants 73,892 stock options to development chief

Rhea-AI Filing Summary

Evommune, Inc. reported that Chief of Development Operations Janice Suzann Drew received an employee stock option grant covering 73,892 shares of common stock. The options carry an exercise price of $26.77 per share and expire on April 15, 2036.

According to the vesting terms, one fourth of the options will vest on the first anniversary of the grant date, with the remaining options vesting in 36 equal monthly installments thereafter, contingent on continued service. Following this grant, the reporting person holds 73,892 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Drew Janice Suzann

Role Chief of Dev. Operations

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	73,892	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 73,892 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 73,892 options Exercise price: $26.77 per share Expiration date: April 15, 2036 +3 more

6 metrics

Option grant size 73,892 options Employee stock option grant to Chief of Development Operations

Exercise price $26.77 per share Stock option exercise price for Evommune common stock

Expiration date April 15, 2036 Option expiration for granted employee stock options

Post-transaction options held 73,892 options Total options held directly after the grant

Initial vesting 25% after 1 year One fourth vests on first anniversary of grant date

Ongoing vesting schedule 36 monthly installments Remaining options vest in equal monthly tranches

Key Terms

Employee Stock Option, grant/award acquisition, vesting, Common Stock

4 terms

Employee Stock Option financial

""Employee Stock Option (Right to Buy)" granted to the officer"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

grant/award acquisition financial

"transaction_action is listed as "grant/award acquisition""

vesting financial

"shares subject to the option award shall vest on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title is identified as "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Drew Janice Suzann

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief of Dev. Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$26.77	04/16/2026		A		73,892		(1)	04/15/2036	Common Stock	73,892	$0.00	73,892	D

Explanation of Responses:

1. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Evommune (EVMN) report in this Form 4?

Evommune reported a stock option grant to its Chief of Development Operations. She received 73,892 employee stock options, giving her the right to buy common shares at a fixed exercise price, as part of her equity-based compensation package.

Who is the Evommune insider involved in this Form 4 filing?

The insider is Janice Suzann Drew, Evommune’s Chief of Development Operations. The filing shows she received a grant of stock options, reflecting compensation rather than an open-market purchase or sale of existing Evommune common shares.

How many Evommune stock options were granted to the officer?

The officer was granted 73,892 employee stock options. Each option represents the right to purchase one share of Evommune common stock, subject to vesting conditions and payment of the stated exercise price when exercised in the future.

What is the exercise price and expiration date of the Evommune options?

The options have an exercise price of $26.77 per share and expire on April 15, 2036. This means the holder can buy Evommune common stock at $26.77, once vested, any time before the April 2036 expiration date.

How do the Evommune stock options granted to the officer vest over time?

One fourth of the options vest on the first anniversary of the grant date. The remaining options vest in 36 equal monthly installments, provided the officer remains in continuous service with Evommune through each applicable vesting date.

What are the officer’s Evommune holdings after this stock option grant?

After the transaction, the officer directly holds 73,892 stock options. These options give her the potential to purchase Evommune common stock in the future, subject to vesting and the payment of the $26.77 per share exercise price.